Cisplatin and novobiocin in the treatment of non-small cell lung cancer. A southwest oncology group study
โ Scribed by Georgiana K. Ellis; Robert B. Livingston; John Crowley; John W. Goodwin; Laura Hutchins; Ace Allen
- Publisher
- John Wiley and Sons
- Year
- 1991
- Tongue
- English
- Weight
- 480 KB
- Volume
- 67
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Patients with advanced breast cancer who had not previously received chemotherapy were treated on a three-arm prospective study: adriamycin day 1 plus 5-FU on day 1 and 8 (AF), adriamycin day 1 , plus 5-FU day 1 and 8 , and cyclophosphamide day 1 (AFC), and adriamycin day 1 plus 5-FU day 1 and 8 , c
A total of 39 patients with non-small cell carcinoma of the lung (NSCL) were treated with cisplatin, etoposide, and mitomycin. A major response rate (complete response + partial response) was seen in 15 patients (39%). Median survival for all patients was 340 days; median survival of the responding